PHASE 2 STUDY OF NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]) IN PATIENTS (PTS) WITH ADVANCED, REFRACTORY SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)

被引：1
|
作者：
Zalcman, G. [1 ]
Rizvi, N. A. [2 ]
Lena, H. [3 ]
Wolf, J. [4 ]
Mazieres, J. [5 ]
Antonia, S. J. [6 ]
Minenza, E. [7 ]
Planchard, D. [8 ]
Lestini, B. J. [9 ]
Ramalingam, S. S. [10 ]
机构：
[1] CHU Caen, Pneumonol, F-14000 Caen, France
[2] Mem Sloan Kettering Canc Ctr, Thorac Oncol, New York, NY 10021 USA
[3] Ctr Hosp Univ Rennes, Oncol & Pulmonol, Rennes, France
[4] Univ Klin Koeln, Pulm Oncol, Cologne, Germany
[5] Ctr Hosp Univ Toulouse, Hop Larrey, Thorac Oncol, Toulouse, France
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Thorac Oncol, Tampa, FL 33682 USA
[7] Osped S Maria, Oncol, Terni, Italy
[8] Gustave Roussy, Thorac Oncol, Villejuif, France
[9] Bristol Myers Squibb Co, Oncol Global Clin Res, Princeton, NJ USA
[10] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv050.8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
104PD
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).
    Spigel, David R.
    Reckamp, Karen L.
    Rizvi, Naiyer A.
    Poddubskaya, Elena
    West, Howard Jack
    Eberhardt, Wilfried Ernst Erich
    Baas, Paul
    Antonia, Scott Joseph
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David Michael
    Ready, Neal
    Gainor, Justin F.
    Aren, Osvaldo Rudy
    Horn, Leora
    Paz-Ares, Luis
    Baudelet, Christine
    Lestini, Brian Joseph
    Brahmer, Julie R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
    Rizvi, Naiyer A.
    Gettinger, Scott N.
    Goldman, Jonathan W.
    Hellmann, Matthew D.
    Chow, Laura Q.
    Juergens, Rosalyn
    Borghaei, Hossein
    Brahmer, Julie R.
    Shen, Yun
    Harbison, Christopher
    Nathan, Faith
    Ready, Neal
    Antonia, Scott J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S176 - S176
  • [3] CLINICAL ACTIVITY AND SAFETY OF ANTI-PROGRAMMED DEATH-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Gettinger, S.
    Horn, L.
    Antonia, S. J.
    Spigel, D.
    Gandhi, L.
    Sequist, L. V.
    Wigginton, J. M.
    Kollia, G.
    Gupta, A.
    Brahmer, J. R.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 405 - 406
  • [4] First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.
    Gettinger, Scott N.
    Hellmann, Matthew David
    Shepherd, Frances A.
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Chow, Laura Quan Man
    Goldman, Jonathan Wade
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Ready, Neal
    Gerber, David E.
    Nathan, Faith Ellen
    Shen, Yun
    Harbison, Christopher
    Rizvi, Naiyer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
    Takuma Imakita
    Kohei Fujita
    Takanori Ito
    Zentaro Saito
    Issei Oi
    Osamu Kanai
    Hiromasa Tachibana
    Satoru Sawai
    Tadashi Mio
    [J]. Discover Oncology, 14
  • [6] Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
    Imakita, Takuma
    Fujita, Kohei
    Ito, Takanori
    Saito, Zentaro
    Oi, Issei
    Kanai, Osamu
    Tachibana, Hiromasa
    Sawai, Satoru
    Mio, Tadashi
    [J]. DISCOVER ONCOLOGY, 2023, 14 (01)
  • [7] Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
    Rajan, Arun
    Kim, Chul
    Heery, Christopher R.
    Guha, Udayan
    Gulley, James L.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (09) : 2219 - 2231
  • [8] Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibodies in Treating Advanced Melanoma
    Metcalfe, Whitney
    Anderson, Jaime
    Van Anh Trinh
    Hwu, Wen-Jen
    [J]. DISCOVERY MEDICINE, 2015, 19 (106) : 393 - 401
  • [9] Clinical Outcomes of Anti-programmed Death-1 Antibody–Related Pneumonitis in Patients with Non-Small Cell Lung Cancer
    Takafumi Koyauchi
    Naoki Inui
    Masato Karayama
    Yoshihiro Kitahara
    Sho Takuma
    Yusuke Amano
    Hideki Yasui
    Hironao Hozumi
    Yuzo Suzuki
    Kazuki Furuhashi
    Tomoyuki Fujisawa
    Noriyuki Enomoto
    Yutaro Nakamura
    Mitsuru Niwa
    Nao Inami
    Yasuhiro Ito
    Hideki Kusagaya
    Shun Matsuura
    Yusuke Kaida
    Tomohiro Uto
    Dai Hashimoto
    Takashi Matsui
    Kazuhiro Asada
    Hiroyuki Matsuda
    Masato Fujii
    Mikio Toyoshima
    Takafumi Suda
    [J]. SN Comprehensive Clinical Medicine, 2020, 2 (5) : 570 - 578
  • [10] Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
    Lee, Yong Jun
    Lee, Jii Bum
    Ha, Sang-Jun
    Kim, Hye Ryun
    [J]. MOLECULES AND CELLS, 2021, 44 (05) : 363 - 373
12345